Clinical trial for MDM2-amplified cancers is expected to begin in 2021
NEWARK, Calif. , June 2, 2021 (GLOBE NEWSWIRE) – Rain Therapeutics Inc. (“Rain”), a clinical-stage company approaching precision oncology treatments, today announced a patient referral partnership with Caris Life Sciences (“Caris” Under the terms of the partnership, Caris will provide patient referral facilities with its molecular intelligence (MI) testing platform for Rain’s phase 2 MDM2 amplified tumor basket trial for RAIN-32 , an oral MDM2 inhibitor in patients with safe counterfeit tumors with specified MDM2 pre-degrees of amplification and wild-type p53.
“We are excited to partner with Caris, a company that stores our precision oncology project, to identify patients for our tumor amplification agnostic basket strategy, amplified through MDM2,” said Robert Doebele, MD, Ph. D. , Rain’s co-founder, president and lead clinical director. “Sequencing tests of the total exome and total transcriptome of Caris will be critical to recruitment for the Phase 2 study, which is expected to begin in 2021. “
“Caris puts the patient in the middle of everything we do, and we are excited to join Rain in this new independent tissue clinical trial,” said Brian Lamon, Ph. D. , chief commercial officer, director of business development for BioPharma for automobiles. East. ” As a pioneer and leader in the molecular profiling industry, this union is based on our project to save and prolong the lives of patients through the maximum comprehensive molecular and synthetic intelligence that can be had in the industry. “
About RAIN-32RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, a double-minute oral mouse 2 inhibitor (MDM2), which is oncogenic in many cancers. 2020 on the effects of a phase 1 clinical trial, which demonstrated significant antitumor activity in a subtype of liposarcoma (LPS) amplified through MDM2 and other counterfeit tumors. This trial also validated a rational dosing regimen that has been shown to mitigate protective considerations and expand the healing window of MDM2 inhibition, through the release of the possibility of RAIN-32 in a wide variety of MDM2-dependent cancers. Based on these data, we plan to begin a pivotal Phase 3 trial in lps by 2021, a phase 2 agnostic basket trial in counterfeit tumors decided in the current part of 2021, and a phase 2 trial in sarcoma of the intima through early year. 2022. RAIN-32 has earned orphan drug designation from the U. S. Food and Drug Administration. U. S. (FD A) for patients with liposarcoma.
About Rain Therapeutics Inc. Rain Therapeutics Inc. es a clinical-stage precision oncology company that develops treatments targeting oncogenic points for which it is able to genetically choose the patients it says will gain the most benefits. This technique includes the use of a tumor. The agnostic strategy for choosing patients is based on the underlying genetics of their tumor rather than histology. Rain’s main candidate product, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, an oral MDM2 inhibitor, which is oncogenic in many cases. In addition to RAIN-32, Rain is also developing a preclinical program aimed at inducing artificial lethality in cancer cells by inhibiting RAD52. For more information, visit www. rainthera. com.
About Caris Life Sciences Caris Life Sciences® is a leading molecular science and synthetic intelligence innovator that aims to deliver on the promise of precision medicine through quality and innovation. The company’s suite of molecular profiling offerings assesses the DNA, RNA and proteins to reveal a molecular trend that is helping doctors and cancer patients make more precise and personalized medicine decisions. Sequence the entire MI Exome exome ™ with 22,000 DNA genes and sequence the entire MI Transcriptome ™ with 22,000 RNA genes, as well as cancer-related pathogens, bacteria and viruses research. and the fungi performed on each patient provides the maximum complete and clinically applicable DNA and RNA profile available on the market.
Caris is also advancing precision medicine with Caris synthetic intelligence, combining its market-leading service offering, Caris Molecular Intelligence®, with its patented synthetic intelligence research engine, DEAN ™, to analyze the entire exome, entire transcriptome and entire cancer proteome. The information, combined with mature clinical outcomes in thousands of patients, provides unparalleled molecular responses for patients, physicians, contributors and biopharmaceutical organizations.
Caris Pharmatech ™ is turning the paradigm and streamlining the clinical trial procedure by connecting biopharmaceutical corporations with oncology sites ready for clinical trials. With more than 420 study sites within Caris Pharmatech’s Just-In-Time (JIT) oncology network, biopharmaceutical companies can identify and recruit more patients, faster. Caris Pharmatech’s just-in-time clinical trial responds on immediate site activation and patient recruitment to expedite the drug progression procedure. By implementing Caris’ just-in-time trial comparison system, Caris automatically engage patients in clinical trials and sites may be activated and eligible to enroll patients within one week.
Headquartered in Irving, Texas, Caris Life Sciences has offices in Phoenix, Denver, New York and Basel, Switzerland. Caris supplies in the United States, Europe, Asia and other foreign markets. For more information, visit CarisLifeSciences. com or stay with us on Twitter (@CarisLS).
Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of federal securities laws, including, but not limited to, our expectations regarding our clinical trials. Words like “possibly”, “may also simply”, “will be”, “objective”, “intention”, “deserve”, “may also simply”, “promises”, “estimate”, “predict”, “potential”, “Develop”, “plan” or the negatives of those terms, and similar expressions or statements regarding the intention, confidence or existing expectations, are forward-looking statements. While we believe that such forward-looking statements are reasonable, we deserve not to place undue reliance on such forward-looking statements, which are based on information in our possession as of the date of this press release. These forward-looking statements are based on existing estimates and assumptions and are subject to various dangers and uncertainties (including, but not limited to, those set forth in our filings with the United States Securities and Exposure Commission (the “SEC”), many of which are beyond our control and subject to reposition. Actual effects may also be materially different. Risks and uncertainties include: expectations related to the launch of our Phase 2 clinical trial; expectations related to the association with Caris and other dangers and Known uncertainties in our quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the US SEC We claim the safe harbor coverage contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Responsibility to update or reposition any statement, already a as a result of new data, long-term occasions or otherwise, unless required through aw.
Rain Media Contact: Grace FotiadesLifeSci Communications 1. 646. 876. 5026gfotiades@lifescicomms. com
Caris Life Sciences Media Contact: Lindsey Bailys GCI Health1-212-798-9884lindsey. bailys@gcihealth. com